Margarita Majem, MD, PhD, discusses the patient-reported outcomes with osimertinib in EGFR-mutated non–small cell lung cancer from the pivotal phase 3 ADAURA trial.
Margarita Majem, MD, PhD, a faculty member in the Department of Medical Oncology at the Hospital de la Santa Creu i Sant Pau, discusses the patient-reported outcomes with osimertinib (Tagrisso) in EGFR-mutated non–small cell lung cancer (NSCLC) from the pivotal phase 3 ADAURA trial.
Results from the phase 3 ADAURA trial, which examined the use of osimertinib in resected, EGFR-mutant NSCLC, indicated that patients who received osimertinib had significantly longer disease-free survival compared to patients who received a placebo.
At baseline, patients had nearly the same mean value of quality of life (QoL) as the general population, according to Majem, who virtually presented the findings during the 2021 World Conference on Lung Cancer. When patients were treated with osimertinib, QoL was maintained across all domains evaluated in the analysis, Majem concludes.